Working together to reduce the global burden of kidney cancer
Kidney cancer is a global issue. Every year, 431,000 people worldwide will be diagnosed with kidney cancer.
Click here for shareable information, graphics and materials about kidney cancer for patient organisations worldwide.
The 2024 Global Patient Survey on Kidney Cancer and Growths is now closed
On 15 November the 4th Global Patient Survey on Kidney Cancer and Growths closed. We are thrilled to share 2677 people completed the survey! Thanks to the collective efforts of Partner Organisations, we surpassed the total number of respondents in the 2022 survey by 21%.
The research team has begun the data analysis process and results will be shared in the coming months.
A special thank you to the patients, survivors and caregivers who took the time to complete the survey. Together we are generating the evidence that will help reduce the global burden of kidney cancer.
IKCC Board of Directors Announcement
We are pleased to share news from the IKCC Board of Directors.
Claudia Ungarelli, from ANTURE in Italy, has been appointed to the position of Director (General Board Director) for a term of three years. Claudia first joined the Board in November 2023 for a one-year term as a representative from a Partner Organisation.
Steve Pointon, from Action Kidney Cancer in the United Kingdom, has been appointed to the position of Board Member representative from a Partner Organisation for a term of three years. In this role, Steve will provide input from the perspective of a patient organisation, as well as his own personal experience with kidney cancer.
These updates are effective 1 November 2024.
Save the Date: 2025 Global Kidney Cancer Summit
Mark your calendars. The 2025 Global Kidney Cancer Summit will take place in Madrid, Spain on Friday 4th April – Sunday 6th April 2025.
More details to follow in 2025.
Tweets from @IKCCorg
;
Congratulations and thank you to Dr Cristiane Bergerot of Grupo Oncoclinicas in Brazil and a member of the IKCC Medical Advisory Board for your important contribution to kidney cancer care. This is such an important step to better measure quality of life in clinical trials.
We’re proud to be a partner in the DISCERN project!
Anne Wilson, Secretary/Treasurer of the IKCC, today facilitated a meeting of patient advocates from the Asia Pacific in an attempt to better understand the needs of patient organisations in the region. (1/4)
and attendees were briefed about the work of the IKCC in our mission to empower and support those with #KidneyCancer throughout the world. (3/4)
The meeting was held at #ESMOAsia24 in Singapore, and pictured are IKCC partner organisations @vcare24 and the Korea Kidneycancer Association, as well as Dr. Ranjit Kaur from the Breast Cancer Welfare Association Malaysia. @myesmo @AnneWil87285253 (4/4)
Choosing the right surgical approach for #KidneyCancer depends on many factors, including the size and location of the tumor. Here are some commonly used methods.
Visit our Patient Resource Center at http://www.kidneycan.org for more information and resources.
#AcceleratingCures
If you couldn't attend our #IKCSNA24 meeting last month in Louisville, KY, catch up on the research highlights:
@medpagetoday https://bit.ly/3B7mHhr
@CancerTherAdvsr https://bit.ly/3B9dG7y
A new treatment, called NDI-101150 has been shown to be effective in people with heavily pretreated #kidneycancer (renal cell carcinoma, RCC) when given alone or with pembrolizumab.
To read more:
https://actionkidneycancer.org/new-treatment-for-pretreated-advanced-kidney-cancer-shows-promise/
Did you know?
Kidney cancer is often found by accident.
Kidney cancer is the 14th most prevalent cancer worldwide.
About 59 per cent of kidney cancer cases occur in more developed countries.
Our Global Network
IKCC welcomes every organisation that has an interest in kidney cancer and who pledges to conform to our Code of Conduct. We extend an open invitation to become part of this international network.
Join our mailing list
In the newsletter we highlight news about kidney cancer diagnosis and treatment, and other relevant discussions.